NCT05163548已完成不适用
Early Feasibility Study of the Vivasure PerQseal®+ (PerQseal® Plus) Vascular Closure Device When Used to Achieve Hemostasis of Common Femoral Arteriotomies Created by 14 to 22 F Sheaths in Patients Undergoing Percutaneous Transcatheter Procedures
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 9
- 主要终点
- Safety: Major Access Site Complications
研究概览
简要总结
The objective of this Early Feasibility Study (EFS) is to evaluate the initial safety and preliminary effectiveness of the PerQseal®+ VCD in a small number of subjects when used to achieve hemostasis of common femoral arteriotomies created by 14 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing Percutaneous Transcatheter procedures.
详细描述
This study is a prospective, multi-center, single arm EFS. Patients undergoing a percutaneous trancatheter procedure, requiring an arteriotomy created by 14 - 22 F sheaths (arteriotomies up to approx. 26 F), via the common femoral artery will be screened against the study inclusion/exclusion criteria. If the patient meets study eligibility requirements, they shall be invited to participate, provide informed consent, and shall subsequently be assigned a study ID number. Enrollment will occur at the point where the PerQseal®+ VCD study device first enters the patient's body.
The planned enrollment is 15 treated patients at a maximum of 5 study sites (minimum of 3) located in the United States.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 19 years,
- •Clinically indicated for a large bore interventional transcatheter procedure, e.g., transcatheter aortic valve repair (TAVR) or endovascular abdominal aortic aneurysm repair (EVAR), or thoracic endovascular aneurysm repair (TEVAR) using a percutaneous common femoral arteriotomy created by a 14 to 22 F sheath,
- •Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements,
- •Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.
排除标准
- •Baseline Exclusion Criteria
- •Evidence of systemic bacterial or cutaneous infection, including groin infection Baseline Exclusion Criteria
- •Evidence of systemic bacterial or cutaneous infection, including groin infection,
- •Known bleeding diathesis, definite or potential coagulopathy, platelet count < 100,000/µl or subjects on long term anticoagulants with an INR > 2 within 12 hours prior to index procedure,
- •Significant anemia (hemoglobin < 9 g/dL or hematocrit < 27%), within 24 hours prior to index procedure,
- •Known type II heparin-induced thrombocytopenia,
- •NYHA functional class IV heart failure that is uncontrolled and requires treatment in the Intensive Care Unit, within 24 hours prior to primary procedure,
- •Documented left ventricular ejection fraction < 20%,
- •Unilateral or bilateral lower extremity amputation.
- •Claudication (e.g., Rutherford category 3 or greater), documented untreated iliac or common femoral artery diameter stenosis > 50% or previous bypass surgery/stent placement in the common femoral artery of target leg,
- •Known existing nerve damage in the target leg,
- •Renal insufficiency (Glomerular Filtration Rate ≤ 30 ml/min or baseline serum creatinine > 2.5 mg/dL) or on renal replacement therapy,
- •Known allergy to any of the materials used in the PerQseal®+ device (refer to Instructions for Use),
- •Subject unsuitable for surgical repair of the target leg access site,
- •Subject has undergone a percutaneous procedure greater than 8 F sheath in the target leg, within the 90 days prior to index procedure,
- •Subject has undergone use of an intra-aortic balloon pump through the target leg access site within 90 days prior to the index procedure,
- •Subject has undergone a percutaneous procedure of 8 F sheath or less using an absorbable intravascular closure device for hemostasis, in the target vessel, within the 90 days prior to index procedure,
- •Subject has undergone a percutaneous procedure of 8 F sheath or less using a suture mediated closure device or manual/mechanical pressure for hemostasis in the target leg, within the 30 days prior to index procedure,
- •Evidence of marked tortuosity of the femoral or external iliac artery in the target leg, based on pre-primary procedure CT angiography,
- •Evidence of arterial diameter stenosis > 30% within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,
- •Evidence of anterior wall calcification of the target common femoral artery (other than small, diffuse deposits which in the opinion of the investigator will not impede the vascular closure procedure) within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,
- •Target femoral artery diameter is less than 7 mm in diameter, based on pre-primary procedure CT angiography,
- •Further planned endovascular procedure in the target leg in the 30 days following the index procedure,
- •Subject is enrolled in another investigational medical device or drug study
- •Subject has been previously enrolled in this clinical study.
- •Current COVID-19 infection (with or without symptoms), recent positive test for COVID-19, or recent exposure (within two weeks) to a person with COVID-19 infection.
- •Procedural Exclusion Criteria If any Procedural Exclusion Criteria listed below, then closure with PerQseal®+ device is not permitted.
- •Initial common femoral arterial access achieved with manual palpation or blind arterial stick access, without use of an image guided approach (ultrasound or angiography).
- •Difficult dilation during initial target femoral artery access (e.g., that damages or kinks sheath dilators) while step-dilating up to the large-bore device,
- •During arterial puncture, the target femoral artery suspected to have experienced a back arterial wall needle puncture or underwent > one needle puncture during the primary procedure.
- •Subject has a tissue tract (i.e., estimated distance from skin entry point to arterial anterior surface at arteriotomy) expected to be greater than 8 cm,
- •Significant blood loss requiring transfusion of blood products during primary procedure or within 30 days prior to index procedure,
- •Activated clotting time (ACT) > 300 seconds immediately prior to sheath removal or if ACT measurements are expected to be > 300 seconds for more than 24 hours after index procedure,
- •Target puncture site is in a vascular graft,
- •Target arteriotomy greater than 26 F,
- •Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 15 mm proximal of the bifurcation of the superficial femoral/ profunda femoris artery,
- •Target arteriotomy located at the level or above the inferior epigastric artery and/or beneath or above the inguinal ligament based on bony landmarks (above femoral head on A-P projection),
- •Subjects with an acute hematoma > 4 cm diameter, arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the target access site identified intra-procedurally,
- •Evidence of bleeding around the primary procedure sheath (BARC type 2 or higher),
- •Intra-procedural angiographic evidence of arterial laceration, dissection or stenosis within the femoral artery that would preclude use of the PerQseal®+ device,
- •Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) at the time of planned vascular closure,
- •Systolic blood pressure < 90 mmHg at the time of planned vascular closure.
结局指标
主要结局
Safety: Major Access Site Complications
时间窗: though 30 days
The primary safety endpoint is the rate of major access site complications attributable to the PerQseal® device. As per FDA definitions for Major access site complications.
Efficacy: Time to Haemostasis
时间窗: 20 minutes
Elapsed time in minutes from PerQseal® Introducer sheath removal to first observed cessation of common femoral artery (CFA) bleeding (excluding cutaneous or subcutaneous oozing, and in the absence of a developing hematoma).
次要结局
- Efficacy: PerQseal® Device Technical Success Rate(10 minutes)
- Safety: Incidence of Minor Access Site Complications(through 30 days)
- Efficacy: PerQseal® Treatment Success Rate(through 30 days)
- Efficacy: Time to Device Deployment(20 minutes)
- Efficacy: Time to Ambulation(through 5 day)
- Efficacy: Total Closure Time(40 minutes)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
不适用
PerQseal® Impella Early Feasibility StudyPercutaneous Large Hole Vascular ClosureNCT04818541Vivasure Medical Limited19
招募中
不适用
MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy (EP001)EpilepsyNCT02804230InSightec20
已完成
1 期
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular ResponseChronic Phase Chronic Myeloid LeukemiaNCT01933906Arbeitsgemeinschaft medikamentoese Tumortherapie12
已完成
不适用
European Study to Evaluate Preliminary Safety and Efficacy of Multiple Obalon Gastric Balloons for 12 Weeks as an Aid for Weight LossWeight ControlObesityNCT01718886Obalon Therapeutics, Inc.17
已完成
不适用
Early Feasibility Study to Evaluate the Safety and Efficacy of PAK HD in ESRD PatientsEnd Stage Renal DiseaseESRDNCT06433193Nextkidney S.A.3